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The majority of bacterial multidrug resistance trans-
porters belong to the class of secondary transporters.
LmrP is a proton/drug antiporter of Lactococcus lactis
that extrudes positively charged lipophilic substrates
from the inner leaflet of the membrane to the external
medium. This study shows that LmrP is a true second-
ary transporter. In the absence of a proton motive force,
LmrP facilitates downhill fluxes of ethidium in both
directions. These fluxes are inhibited by other sub-
strates of LmrP. The cysteine-reactive agent p-chloro-
mercuri-benzene sulfonate inhibits these fluxes in wild
type LmrP but not in the cysteine-less LmrP C270A mu-
tant. Cysteine mutagenesis of LmrP resulted in three
mutants, D68C/C270A, D128C/C270A, and E327C/C270A,
with an energy-uncoupled phenotype. Asp68 is located in
the conserved motif GXXX(D/E)(R/K)XGRK for the major
facilitator superfamily of secondary transporters and
was found to play an important role in energy coupling,
whereas the negatively charged residues Asp128 and
Glu327 have indirect effects on the transport process.
L. lactis strains expressing these uncoupled mutants of
LmrP show an increased rate of ethidium influx and an
increased drug susceptibility compared with cells har-
boring an empty vector. The rate of influx in these mu-
tants is enhanced by a transmembrane electrical poten-
tial, inside negative. These observations suggest a new
strategy for eliminating drug-resistant microbial patho-
gens, i.e. the design and use of modulators of secondary
multidrug resistance transporters that uncouple drug
efflux from proton influx, thereby allowing transmem-
brane electrical potential-driven influx of cationic
drugs.
Multidrug resistance transporters (MDRs)1 play a crucial
role in the resistance of prokaryotic and eukaryotic cells
against cytotoxic compounds. In bacteria, including pathogens,
the activities of MDRs contribute to the resistance against
antibiotics (1–4). The control of spread and the prevention of
selection of multidrug resistant strains has become a critical
issue in the battle against contagious diseases (5). To fight
antibiotic resistance efficiently, detailed knowledge of the mo-
lecular mechanisms underlying microbial drug resistance is
required.
Most bacterial MDRs known to date are secondary transport-
ers. For example, LmrP is a proton motive force (pmf)-driven
MDR of Lactococcus lactis (6). LmrP is a member of the major
facilitator superfamily of membrane proteins and shows homol-
ogy to Bmr and NorA, the MDRs of Bacillus subtilis (7) and
Staphylococcus aureus (8), respectively, as well as to the trans-
porters involved in tetracycline resistance and bicyclomycin
resistance in Escherichia coli (9). Cells expressing LmrP have
increased resistance to several clinically important antibiotics
from different pharmacological classes (10), which indicates the
frightening possibility that its homologues in pathogenic bac-
teria may reduce the efficacy of important antibiotics in clinical
settings.
In this study we report that LmrP is a true secondary trans-
porter and is able to mediate active efflux and, under non-
energized conditions, downhill drug influx and efflux. We show
that residue Asp68, located in the cytoplasmic loop between
transmembrane segments (TMS) II and III, is involved in the
energy-coupling mechanism but not in substrate binding,
whereas Asp128 in the cytoplasmic loop between TMS IV and V
is not participating in the binding of ethidium either, but it
might be part of the structural framework responsible for re-
taining a correct folding of the transporter during the transport
cycle. Glu327 appears not to be involved either in the binding of
ethidium or the coupling of proton flux to ethidium transport.
Energy-uncoupled mutants of LmrP were constructed, which
showed increased rates of transmembrane electrical potential
()-driven influx of cationic drugs. The expression of such
uncoupled secondary MDRs is disadvantageous and causes
increased drug susceptibility to the host cells. This observation
may be useful for developing alternative and more efficient
strategies of antibiotic therapies.
EXPERIMENTAL PROCEDURES
Bacterial Strains, Plasmids, and Growth Conditions—L. lactis
NZ9000 (lmrA) (11), which lacks the gene encoding ATP-binding cas-
sette-type MDR transporter LmrA (a kind gift from O. Gajic and J. Kok,
Department of Genetics, University of Groningen), was used in combi-
nation with the NICE system (12, 13) for overexpression of wild type
LmrP (WT LmrP) and the mutant proteins (14, 15). L. lactis cells were
grown at 30 °C in M17 medium (Difco) supplemented with 0.5% (w/v)
glucose and 5 g/ml chloramphenicol. For the growth experiments, the
M17 medium was prepared in 50 mM potassium phosphate (pH 7).
Expression of LmrP variants from pNZ8048-derived plasmids was in-
duced by adding 10 ng of nisin A per milliliter at an A660 of 0.6, and
cells were harvested 60 min after induction.
Recombinant DNA Techniques—General procedures for cloning and
DNA manipulation were performed essentially as described by Sam-
brook et al. (16). The PCR overlap extension method (17) was used to
introduce mutations in the lmrP gene on the pHLP5 expression plasmid
(14), which encodes LmrP with a C-terminal His6 tag. All PCR-ampli-
fied DNA fragments were sequenced to verify that only the intended
changes were introduced. DNA sequencing was performed at the Bio-
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Medical Technology Centre (University of Groningen, Groningen, The
Netherlands).
Preparation of Membrane Vesicles—Membrane vesicles with an in-
side-out orientation were prepared from L. lactis NZ9000 (lmrA) cells
expressing LmrP variants by the French press procedure as described
by Putman et al. (14). The vesicles were frozen in liquid nitrogen and
stored at 80 °C at a protein concentration of 15–35 mg/ml in 50 mM
potassium phosphate, pH 7, containing 10% (w/v) glycerol.
Measurements of Active Transport—For ethidium transport experi-
ments, whole cells expressing LmrP variants were washed with 50 mM
potassium phosphate (pH 7) containing 5 mM MgSO4, and suspended in
the same buffer to an A660 of 0.5. Cells (2 ml) were energized by the
addition of 25 mM glucose. After 2 min, 10 M ethidium was added to the
cell suspension, and the accumulation of ethidium was measured indi-
rectly by following the fluorescence of the ethidium-polynucleotide com-
plex in the cells. Fluorescence was monitored with a PerkinElmer LS
50B fluorometer using excitation and emission wavelengths of 500 and
580 nm, respectively.
Transport of Hoechst 33342 (Molecular Probes Inc.) in inside-out
membrane vesicles was measured as described by Putman et al. (14).
Membrane vesicles (0.5 mg of protein/ml) were suspended in 50 mM
potassium Hepes (pH 7) containing 2 mM MgSO4, 8.5 mM NaCl, 0.1
mg/ml creatine kinase, and 5 mM phosphocreatine. After incubation for
30 s at 30 °C, 1 M Hoechst 33342 was added. Upon the addition of 0.5
mM Mg-ATP, LmrP was activated through the generation of the pmf by
F0F1 H
-ATPase. The amount of membrane-associated Hoechst 33342
was measured fluorometrically (PerkinElmer LS 50B) using excitation
and emission wavelengths of 355 and 457 nm, respectively, and slit
widths of 5 nm each.
Measurements of Passive Fluxes—Cells were grown as described for
measurements of active transport of ethidium. After the wash step, cells
were resuspended to an A660 of 1. Cells present in 2 ml of this suspen-
sion were pelleted by centrifugation and loaded with 25 M ethidium for
30 min at 30 °C in the final volume of 400 l of 50 mM potassium
phosphate (pH 7) containing 5 mM MgSO4. To determine the influence
of p-chloromercuri-benzene sulfonate (pCMBS) on passive fluxes of
ethidium, the cell suspension was incubated for an additional 5 min
with 0.5 mM freshly dissolved pCMBS prior to or after incubation with
ethidium for influx and efflux experiments, respectively. After loading
with ethidium, cells were pelleted by centrifugation in a table centri-
fuge (2 min at 14,000 rpm), and resuspended in 100 l of 50 mM
potassium phosphate (pH 7) containing 5 mM MgSO4. For fluxes, meas-
urements 50 l from this cell suspension were used.
Determination of the Growth Rate—For the determination of growth
rate in the presence of ethidium, cells were grown in microtiter plates
as described (18). Overnight cultures of L. lactis NZ9000 (lmrA),
harboring pNZ8048, pHLP5, pHLP5::D68C/C270A, pHLP5::D128C/
C270A, and pHLP5::E327C/C270A (14, 15) were diluted into fresh
medium and grown to mid-exponential phase. The cells were diluted in
fresh medium to an A660 of 0.05, and 150-l aliquots of the cell suspen-
sion were transferred to sterile low protein binding 96-well microplates
(Garneir, Germany) containing 50 l of various concentrations of
ethidium in fresh medium. For the induction of expression of LmrP,
nisin (Sigma) was added to a final concentration of 100 pg/ml. Aliquots
(50 l) of sterile silicon oil were pipetted on top of the sample to prevent
evaporation. The cells were grown at 30 °C, and the cell densities were
monitored by measuring the absorbance at 690 nm every 10 min for
16 h in a multiscan photometer (Molecular Devices, Spectra Max 340).
The ethidium concentration that inhibits the growth rate by 50% (IC50
value) was determined.
RESULTS
Wild Type LmrP Is Sensitive to pCMBS—Wild type LmrP
contains one native cysteine residue, Cys270, which is not ac-
cessible to the cysteine-reactive agent fluorescein maleimide
and is most likely located in the putative TMS VIII (Fig. 1) (15).
In a previous report (15), a cysteine-less mutant, C270A, was
described that retained significant transport activity and was
expressed to similar levels as wild type LmrP. To evaluate the
role of Cys270, the effects of several cysteine-reactive agents
were tested on LmrP-mediated transport of Hoechst 33342 and
ethidium. These compounds are good substrates of LmrP and
can be used for transport studies in whole cells and inside-out
membrane vesicles (6, 14, 19).
Hoechst 33342 is highly fluorescent when present in the lipid
environment of membranes but essentially non-fluorescent in
the aqueous phase. Transport of Hoechst 33342 from the mem-
brane into the aqueous phase can therefore be followed in
membrane vesicles by monitoring the Hoechst 33342 fluores-
cence over time. The addition of ATP to inside-out membrane
vesicles of L. lactis results in the generation of a pmf through
proton pumping by the F1F0-ATPase. This pmf drives the
transport of Hoechst 33342 by LmrP out of the membrane as
indicated by the decrease in Hoechst 33342 fluorescence (Fig.
2). Wild type LmrP-mediated Hoechst 33342 transport was not
affected by [2-(trimethylammonium)ethyl]methanethiosulfon-
FIG. 2. Influence of pCMBS on transport of Hoechst 33342 in
inside-out membrane vesicles prepared from cells expressing
the WT and the cysteine-less variant (C270A) of LmrP. Membrane
vesicles (20 mg of protein per milliliter) were incubated with or without
0.5 mM pCMBS for 5 min at 30 °C. Vesicles were subsequently washed
once with 50 mM potassium phosphate, pH 7, and suspended to 0.5 mg
protein/ml in the buffer for Hoechst 33342 transport (see ‘‘Experimental
Procedures’’). Hoechst 33342 (1 M) was added, and its binding to the
membrane vesicles was followed in time until a steady state was
reached. Hoechst 33342 transport was initiated by the addition of 0.5
mM Mg-ATP. Dotted lines, WT LmrP; dashed lines, mutant C270A;
minus sign (), not treated with pCMBS; and plus sign (), treated
with pCMBS.
FIG. 1. Secondary structure model
of LmrP. Acidic residues and the native
cysteine are indicated. The model is based
on the hydropathy profile of the amino
acid sequence, the distribution of the ar-
ginine and lysine residues according to
the ‘‘positive inside rule’’ (6), and the ac-
cessibility of cysteine mutants for mem-
brane-impermeant, cysteine-reactive
agents (15). Circled letters are single-
letter amino acid designations accompa-
nied by their position numbers.
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ate, 2-aminoethyl-methanethiosulfonate, or N-ethylmaleimide
(data not shown), whereas pCMBS, a cysteine-reactive mercu-
rial compound, inhibited Hoechst 33342 transport completely
(Fig. 2). Inhibition of transport by pCMBS appears to be due to
the reaction of Cys270 with pCMBS (Fig. 2), because pCMBS
did not affect the generation of the pmf in inside-out membrane
vesicles (data not shown) and did not inhibit Hoechst 33342
transport by the cysteine-less LmrP mutant C270A.
The effect of pCMBS on LmrP-mediated ethidium fluxes was
also investigated. Ethidium crosses the membrane passively
and intercalates subsequently into cellular polynucleotides,
whereupon it becomes highly fluorescent. Ethidium transport
in whole cells can be measured indirectly by monitoring the
fluorescence of this intracellular ethidium-polynucleotide com-
plex. Cationic compounds such as ethidium are electrophoreti-
cally imported into energized bacterial cells, and this process is
driven by the  (inside negative). Consequently, significant
levels of accumulation of cationic compounds can occur even in
the absence of an active uptake system (20, 21). Binding of
ethidium to the cellular polynucleotides can further contribute
to drug accumulation in cells relative to the environment.
Ethidium accumulation by LmrA-deficient, glucose-energized
cells expressing the WT LmrP and nonexpressing control cells
demonstrated that WT LmrP can reduce the accumulation of
ethidium in the cell by excreting this cationic compound (Fig.
3A) (6, 22). Also the C270A variant of LmrP is capable of
reducing the cellular accumulation of ethidium, indicating that
this mutant has retained significant transport activity (Fig.
3A) (15). The extrusion of ethidium is dependent on the pres-
ence of a pmf. In the absence of metabolic energy, ethidium is
not actively extruded, and only the influx of ethidium across
the membrane occurs. In control cells lacking LmrP, the influx
of ethidium under non-energized conditions is very slow (Fig.
3B). On the other hand, non-energized cells expressing the WT
or cysteine-less variant of LmrP have drastically higher rates
of ethidium influx (Fig. 3B). Similar observations were made
for the ethidium flux in the opposite direction. Under non-
energized conditions, the rates of ethidium efflux were signifi-
cantly lower from ethidium-preloaded, LmrP-nonexpressing
FIG. 4. Effect of expression of WT and mutants of LmrP on
ethidium accumulation in energized L. lactis cells. The cells were
pre-energized for 2 min in the presence of 25 mM glucose, after which 10
M ethidium was added. Solid line, cells harboring empty vector; dotted
line, cells expressing WT LmrP; dash-dot line, cells expressing mutant
D68C/C270A; long dashed line, cells expressing mutant D128C/C270A;
and dash-double dot line, cells expressing E327C/C270A mutant. A.U.,
arbitrary units.
FIG. 3. Fluxes of ethidium in energized and non-energized cells of L. lactis. Binding of ethidium to the nucleic acids was followed
fluorometrically. A, accumulation of ethidium under energized conditions. Cells were pre-energized for 2 min in the presence of 25 mM glucose, after
which 10 M ethidium was added. B, influx of ethidium into non-energized cells. C, efflux of ethidium from non-energized cells. The cells were
pre-loaded with ethidium (25 M) for 30 min at 30 °C, spun down, suspended in 100 l of buffer, and immediately transferred to the measurement
cuvette. D, effect of pCMBS on influx of ethidium into non-energized cells. Cells were challenged with 0.5 mM pCMBS for 5 min at 30 °C, washed
twice with 50 mM potassium phosphate, pH 7, and then used for measurements of ethidium transport. E, the influence of pCMBS on the efflux of
ethidium from non-energized cells. After loading with ethidium, 0.5 mM pCMBS was added to the cell suspension followed by 5 min of incubation
at 30 °C and two washings with 50 mM potassium phosphate, pH 7, and then used for measurements of ethidium transport. F, inhibition of efflux
of ethidium from preloaded cells by verapamil. After loading with ethidium, 1 M verapamil was added to the cell suspension followed by 5 min
of incubation at 30 °C. The cells were washed twice with 50 mM potassium phosphate, pH 7, containing 1 M verapamil and then used for
measurements of ethidium efflux in the presence of 1 M verapamil. Solid lines, cells harboring empty vector; dotted lines, cells expressing WT
LmrP; dashed lines, cells expressing mutant C270A; minus sign (), not treated with pCMBS; plus sign (), treated with pCMBS; and A.U.,
arbitrary units.
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cells than from ethidium-preloaded WT LmrP and LmrP
C270A mutant-expressing cells (Fig. 3C). The rates of the
ethidium fluxes were proportional to the level of expression of
LmrP (data not shown). These observations demonstrate that
LmrP facilitates the flux of ethidium across the membrane in
the absence of a pmf. Additional evidence that the ethidium
flux is, to a large extent, LmrP-mediated was obtained by
treatment of cells with pCMBS. pCMBS did not affect ethidium
fluxes in control cells not expressing LmrP or in cells express-
ing C270A mutant LmrP, whereas it decreased drastically the
fluxes of ethidium in cells expressing the WT LmrP (Figs. 2 and
3, D and E). These ethidium fluxes were inhibited by tetraphe-
nylphosphonium, a well known substrate of LmrP (22), and the
inhibitor verapamil (23), providing further support for the pro-
posal that LmrP mediates facilitated fluxes of ethidium in
non-energized cells (Fig. 3F and data not shown).
Energy-uncoupled Mutants of LmrP Also Facilitate Drug In-
flux in Energized Cells—Recently, the interesting observation
was made that energized cells of L. lactis expressing variants of
LmrP C270A with a single cysteine substitution2 (D68C/
C270A, D128C/C270A, or E327C/C270A) accumulated ethi-
dium rapidly (Fig. 4) (15), whereas WT LmrP extrudes
ethidium under these conditions. The ethidium influx rates
into these cells were comparable with the influx rates observed
in non-energized cells expressing WT LmrP (Fig. 3B).
These data indicate that the cysteine mutants D68C/C270A,
D128C/C270A, and E327C/C270A are energy-uncoupled and
capable of catalyzing only a facilitated diffusion of substrates.
It is noteworthy that the influx rates into cells expressing these
mutant proteins are slightly lower under non-energized condi-
tions than under energized conditions (compare Figs. 4 and 5),
which is consistent with the notion that the  (inside nega-
tive) accelerates the facilitated diffusion process of this posi-
tively charged substrate.
Sensitivity of Single Cysteine Mutants to pCMBS—The ef-
fects of pCMBS on ethidium fluxes in L. lactis cells expressing
the single cysteine mutants of LmrP were also investigated
(Fig. 5). pCMBS (0.5 mM) strongly inhibited the influx and
efflux of ethidium in cells expressing the D68C/C270A mutant
or WT LmrP (Fig. 5, A and D). In contrast, pCMBS did not
inhibit either influx or efflux of ethidium in cells expressing
D128C/C270A (Fig. 5, B and E) or E327C/C270A (Fig. 5, C and
F) mutants. Labeling of residues D128C/C270A and E327C/
C270A by fluorescein maleimide could be prevented by prein-
cubation of protein with pCMBS, demonstrating that both res-
idues are accessible to this mercurial (data not shown).
Phenotype of D68C, D128C, and E327C Mutants of LmrP—
To investigate whether the observed uncoupled phenotype of
the D68C/C270A, D128C/C270A, and E327C/C270A mutants
was caused by changing two residues in LmrP, the mutations
giving an uncoupled phenotype in the cysteine-less background
of the mutant C270A were also introduced into WT LmrP
possessing Cys270. All three mutants were expressed to levels
similar to that of WT LmrP (data not shown). The D68C mu-
tant retained the uncoupled phenotype of the D68C/C270A
mutant, whereas the D128C mutant catalyzed facilitated dif-
fusion of ethidium into energized cells, but to a lower extent
than the D128C/C270A mutant did. Unexpectedly, the E327C
mutant exhibited a high transport activiy of ethidium (Fig. 6),
indicating that both mutations are responsible for the uncou-
pled phenotype of the E327C/C270A mutant.
Cells Expressing the Energy-uncoupled Mutants of LmrP Are
More Susceptible to Ethidium—Because the LmrP mutants
D68C/C270A, D128C/C270A, and E327C/C270A facilitate in-
flux of ethidium, cells expressing these mutants should be more
sensitive to drugs than nonexpressing control cells. To test this
hypothesis, we followed the effects of ethidium on the growth of
L. lactis NZ9000 (lmrA) harboring the empty vector pNZ8048
or its derivatives encoding WT LmrP or mutants D270A, D68C/
C270A, D128C/C270A, and E327C/C270A (Fig. 7). Concentra-
tions of ethidium that resulted in a 50% reduction of the growth
rates (IC50) are given in Table I. For cells harboring the empty
2 It should be noted that the annotation of the cysteine mutants used
in this manuscript differs from the annotation used in Ref. 15 (D68C/
C270A was D68C, D128C/C270A was D128C, and E327C/C270A was
E327C).
FIG. 5. Fluxes of ethidium in non-energized L. lactis cells expressing mutants of LmrP without () and after () incubation with
0.5 mM pCMBS. Solid line, cells harboring empty vector; dashed lines, cells expressing mutants. Panels A, B, and C, influx of ethidium into cells
expressing D68C/C270A, D128C/C270A, and E327C/C270A mutants of LmrP, respectively. Panels D, E, and F, efflux of ethidium from preloaded
cells expressing D68C/C270A, D128C/C270A, and E327C/C270A mutants of LmrP, respectively. A. U., arbitrary units.
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vector, the IC50 was 6.5 M; the IC50 increased to 11 M for cells
expressing WT LmrP and to 7.8 M for cells expressing C270A
LmrP. In contrast, cells expressing LmrP mutants D68C/
C270A, D128C/C270A, and E327C/C270A were significantly
more sensitive to ethidium than the control cells not expressing
LmrP and displayed IC50 values of 1.9, 2, and 3.2 M,
respectively.
DISCUSSION
In this study the sensitivity of WT LmrP to pCMBS was used
to demonstrate that LmrP plays a major role in the high fluxes
of ethidium across the membranes under non-energized condi-
tions. Ethidium accumulation was followed by measuring flu-
orescence of the cellular ethidium-polynucleotide complex. The
influx of ethidium into (Fig. 3D) and the efflux of ethidium out
of non-energized cells (Fig. 3E) were blocked upon the incuba-
tion of cells with pCMBS in cells expressing WT LmrP but not
in cells expressing the cysteine-less mutant C270A. The rate of
facilitated diffusion of ethidium under non-energized condi-
tions increased with the expression levels of LmrP, and the
ethidium fluxes are inhibited by other substrates of LmrP.
Furthermore, we have generated LmrP mutants that are en-
ergy-uncoupled. These mutants facilitate rapid entry and exit
of drugs into and out of the cell but are unable to secrete the
drugs against their concentration gradient. These mutants re-
semble previously described energy-uncoupled mutants of the
lactose permease (24, 25) and demonstrate that LmrP behaves
as a true secondary transporter capable of mediating facilitated
diffusion of substrates in both directions, depending on the
direction of the substrate gradient.
Cells expressing a single cysteine variant of C270A LmrP
(D68C/C270A, D128C/C270A, or E327C/C270A) rapidly accu-
mulate ethidium under both non-energized and energized con-
ditions (Figs. 4 and 5, A–C) and clearly exhibit an energy-
uncoupled phenotype. However, the influx of ethidium is
slower under non-energized conditions than under energized
conditions, suggesting that the  (inside negative) pulls cati-
onic drugs into the cells (20, 21). These data also demonstrate
that the negatively charged residues Asp68, Asp128, and Glu327
are not essential for ethidium binding. pCMBS inhibited the
facilitated diffusion of ethidium in the D68C/C270A mutant,
but not in the D128C/C270A and E327C/C270A mutants (Fig.
5). Because these residues are all accessible to pCMBS (data
not shown), it appears that Asp128 and Glu327 are not in close
proximity to either the binding site for ethidium or the sub-
strate translocation pathway. To determine whether the un-
coupled behavior of the single cysteine variants D68C/C270A,
D128C/C270A, and E327C/C270A of LmrP is due to introduc-
tion of two mutations, i.e. an acidic amino acid to cysteine and
the native Cys270 to alanine, an additional set of mutants was
constructed, namely D68C, D128C, and E327C using WT LmrP
as the template. One of these mutants, D68C, catalyzed the
facilitated diffusion of ethidium into energized cells (Fig. 6),
confirming a role of the Asp68 in the energy-coupling mecha-
nism. Asp68 is part of the conserved motif, GXXX(D/E)(R/
K)XGRK, located in the cytoplasmic loop between TMS II and
TMS III of the major facilitator superfamily of secondary trans-
porters that are involved in the transport of a variety of com-
pounds (26). The function of this motif has been extensively
studied in other transporters. It is of interest to note that, for
the tetracycline transporter TetA(B), it has been demonstrated
that Asp66 (homologous to Asp68 in LmrP) does not directly
participate in substrate binding but is part of the gating mech-
anism of TetA(B) (27). Moreover, N-ethylmaleimide labeling of
a cysteine residue introduced next to the Asp66 in TetA(B)
inhibited tetracycline transport, further suggesting that this
region is essential for coupling transport to the pmf. In the
E. coli lactose permease (LacY), substitutions of the conserved
Asp68 almost completely abolish transport activity of lactose
permease (28, 29). However, these mutants have not been
reported to be uncoupled and display very low rates of downhill
transport of lactose (28, 29). Conservation of this motif among
members of the major facilitator superfamily suggests that this
region is not directly involved in substrate binding but, instead,
may be critical in facilitating conformational changes following
TABLE I
Ethidium susceptibilities of L. lactis NZ9000 ( lmrA) harboring
vector pNZ8048 and its derivatives encoding WT LmrP and the
mutants C270A, D68C/C270A, D128C/C270A, and E327C/C270A










M M M M M M
IC50 6.5  0.2 11  0.2 7.8  0.4 1.9  0.4 2  0.4 3.2  0.3
FIG. 6. Ethidium accumulation in energized L. lactis cells ex-
pressing WT and mutants of LmrP containing the endogenous
Cys270. The cells were pre-energized for 2 min in the presence of 25 mM
glucose, after which 10 M ethidium was added. Solid line, cells har-
boring empty vector; dotted line, cells expressing WT LmrP; dash-dot
line, cells expressing mutant D68C; long dashed line, cells expressing
mutant D128C; dash-double dot line, cells expressing E327C mutant;
and A.U., arbitrary units.
FIG. 7. Resistance of L. lactis NZ9000 (lmrA) to ethidium.
Cells carrying empty vector pNZ8048 (filled circle), plasmids coding for
WT LmrP (inverted triangle), and the mutants C270A (square), D68C/
C270A (diamond), D128C/C270A (triangle), and E327C/C270A (penta-
gon) were grown in M17 medium in the presence of different concen-
trations of ethidium. The relative growth rate is plotted as a function of
the drug concentration. The data are from two independent experi-
ments. The increase of viability of the cells expressing WT LmrP at low
concentrations of ethidium was reproducible and observed in many
experiments.
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substrate binding (30). The motif is connected with TMS II,
which undergoes a conformational change upon interaction of
lactose permease with ligands (25, 31) and faces the substrate
binding cavity (32). We hypothesize that mutation D68C alters
the structure of the loop connecting TMS II and TMS III and
further disturbs the orientation of these two TMSs, thereby
interfering with the coupling between the H flux and sub-
strate translocation. The D128C mutant appeared to be less
efficient in facilitating influx of ethidium into energized cells
than the D128C/C270A mutant (compare Figs. 4 and 6). At this
stage, the function of Asp128 remains obscure. For the TetA(B)
transporter, it has been proposed that Asp120 (corresponding to
Asp128 in LmrP) forms an ion pair with an arginine residue
present in a loop region between TMS II and TMS III, thereby
ensuring a correct structure of the protein (33, 34). The third
mutant, E327C, extrudes ethidium efficiently (Fig. 6), ruling
out a role of Glu327 in proton translocation or ethidium binding.
However, the presence of a negative charge at this location is
critical for the interaction of LmrP with the divalent cation
Hoechst 33342 (15), suggesting that Glu327 is part of the sub-
strate binding pocket of LmrP. The two mutations in the
E327C/C270A mutant thus seem to affect the conformation in
this binding region in such a way that pmf-driven transport of
ethidium and Hoechst 33342 is no longer possible. In summary,
the uncoupled phenotype of mutants D68C and D128C is most
likely the result of structural perturbations within LmrP, and
these residues most likely do not play a direct role in H
translocation.
The observations describe above demonstrate that mutations
of the native cysteine in LmrP, Cys270, somehow affect the
activity of the transporter. In a previous study (15), we have
shown that Cys270 is not accessible to fluorescein maleimide
labeling and, therefore, is most likely membrane-embedded. In
this report we tested several other cysteine-reactive com-
pounds to probe the role of Cys270, but only pCMBS was found
to inhibit the transport activity of WT LmrP. Because pCMBS
had no effect on the activity of the cysteine-less mutant C270A,
we conclude that this mercurial targets Cys270. This residue is
likely located in a transmembrane region of the protein that is
poorly accessible to the water phase, because the maleimide
probes were not effective (35, 36). Nevertheless Cys270 is not
essential for transport, as the C270A mutant showed substan-
tial activity. Inhibition of transport by pCMBS could be due to
the location of Cys270 close to a substrate binding site or to the
translocation pathways of substrates and/or protons. A location
in the substrate binding site seems unlikely, because the affin-
ity of the C270A mutant for Hoechst 33342 is unchanged upon
reaction with pCMBS.3 Alternatively, pCMBS-labeling of
Cys270 may interfere with conformational changes of LmrP
during the transport cycle. It is noteworthy that the significant
Hoechst 33342 and ethidium transport activity of the C270A
mutant excludes a direct role of Cys270 in proton translocation.
One conclusion of our work is that the presence of a second-
ary WT MDR, such as LmrP, causes the rapid influx of drugs
under non-energized conditions. This observation demon-
strates that LmrP is a proper secondary transporter and me-
diates active transport and, in the absence of pmf, downhill
fluxes of substrates. These modes of transport are typical for
secondary transporters and have been described previously (37,
38). Notably, we report here a new important finding that
expression of an uncoupled MDR increases the sensitivity of
cells to ethidium even under energized conditions. Clearly,
expression of such an energy-uncoupled secondary MDR allows
a membrane potential-driven accumulation of a toxic cationic
substrate in cells. Consequently these cells are more suscepti-
ble to drugs than cells that do not express the transporter at
all. On the contrary for neutral substrates, as reported for
uncoupled mutants of lactose permease, only fluxes down a
chemical substrate gradient or exchange reaction are possible
(39). For a neutral substrate, such concentration-driven fluxes
do not lead to accumulation in cells. This knowledge may be
used to develop new strategies in the battle against multidrug-
resistant pathogens. Modulators of secondary MDRs, which do
not compete with the antibiotic for the same binding site but
uncouple drug efflux from proton influx, will allow -driven
accumulation of cationic antibiotic substrates, resulting in an
increased drug sensitivity of the pathogens.
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